NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
Among the four patients who received the autologous TILs + nivolumab combination, three (75%) achieved an objective response (two achieved a partial response [PR] at the end of the study, two achieved a complete response [CR]), and one achieved a CR at the end of the study. Among these three patients, one had a PR, and two had stable disease (SD) after the nivolumab course and before any TILs administration, reinforcing the importance of the tumour response after TILs injection. These responses were persistent, ranging from 9 months to 3.4 years.
Authors
- Julie Cassecuel
- Brigitte Dréno (ORCID: https://orcid.org/0000-0001-5574-5825)
- A. Dompmartin (ORCID: https://orcid.org/0000-0003-0081-500X)
- Soraya Saïagh
- J.-M. L’Orphelin (ORCID: https://orcid.org/0000-0002-5680-7888)
- Jean‐Michel Nguyen (ORCID: https://orcid.org/0000-0001-8815-7640)
- Ugo Lancien (ORCID: https://orcid.org/0000-0003-1262-5510)
- Francisco Javier Saenz Coronilla
- Lise Boussemart (ORCID: https://orcid.org/0000-0002-6895-0139)
Institutions
- Inserm (FR)
- Normandie Université (FR)
- Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers
- Nantes Université (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2024-11-07
- DOI
- https://doi.org/10.2340/1651-226x.2024.40495
- Citations
- 14
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.96